Profile data is unavailable for this security.
About the company
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
- Revenue in USD (TTM)0.00
- Net income in USD-25.90m
- Incorporated1998
- Employees29.00
- LocationOncolytics Biotech Inc1167 Kensington Cres Nw Suite 210Calgary Alberta Canada T2n 1X7CALGARY T2R 0C5CanadaCAN
- Phone+1 (403) 670-7377
- Fax+1 (403) 283-0858
- Websitehttps://www.oncolyticsbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 103.35m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Korro Bio Inc | 7.37m | -88.42m | 105.19m | 87.00 | -- | 1.06 | -- | 14.27 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Agenus Inc | 106.83m | -35.38m | 105.53m | 316.00 | -- | -- | -- | 0.9879 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Citius Oncology Inc | 0.00 | -24.76m | 107.70m | -- | -- | 2.27 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Cardiff Oncology Inc | 501.00k | -50.45m | 107.78m | 32.00 | -- | 2.20 | -- | 215.12 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 108.17m | 341.00 | -- | 1.61 | -- | 0.8476 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Codexis Inc | 52.93m | -63.95m | 108.39m | 188.00 | -- | 2.81 | -- | 2.05 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| Immunic Inc | 0.00 | -103.05m | 109.76m | 91.00 | -- | 8.57 | -- | -- | -0.8362 | -0.8362 | 0.00 | 0.1064 | 0.00 | -- | -- | 0.00 | -195.41 | -83.24 | -396.11 | -96.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.37 | -- | 36.85 | -- |
| Coya Therapeutics Inc | 3.99m | -18.43m | 110.44m | 8.00 | -- | 2.89 | -- | 27.69 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 110.61m | 134.00 | -- | -- | -- | 606.66 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Oncolytics Biotech Inc | 0.00 | -25.90m | 114.06m | 29.00 | -- | 1,300.77 | -- | -- | -0.288 | -0.288 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Genelux Corp | 0.00 | -31.87m | 116.70m | 24.00 | -- | 5.28 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 117.84m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 119.82m | 44.00 | -- | 2.64 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 126.48m | 24.00 | 6.12 | 1.00 | 5.79 | 1.81 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Oncolytics Biotech Inc's reporting currency: US Dollar USD
1.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 30 Sep 2025 | 381.87k | 0.36% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 363.69k | 0.34% |
| Marshall Wace LLPas of 30 Sep 2025 | 323.98k | 0.30% |
| Seeds Investor LLCas of 31 Dec 2025 | 258.31k | 0.24% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 208.70k | 0.19% |
| International Assets Investment Management LLCas of 31 Dec 2025 | 208.15k | 0.19% |
| Quadrature Capital Ltd.as of 30 Sep 2025 | 106.08k | 0.10% |
| Fiduciary Trust Company of Canadaas of 30 Sep 2025 | 69.84k | 0.07% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 68.23k | 0.06% |
| Geode Capital Management LLCas of 30 Sep 2025 | 66.94k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
